Adjuvant abemaciclib (Verzenio) plus endocrine therapy significantly reduced the risk of death by 15.8% compared with endocrine therapy alone in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer (HR, 0.842; 95%…
Abemaciclib Plus Endocrine Therapy Provides OS Benefit in HR+/HER2-Negative Breast Cancer
